These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011 [TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer. Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
8. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
9. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. Hu WD; Wang HC; Wang YB; Cui LL; Chen XH Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535 [TBL] [Abstract][Full Text] [Related]
10. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer. Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685 [TBL] [Abstract][Full Text] [Related]
11. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab. Eude F; Guisier F; Salaün M; Thiberville L; Pressat-Laffouilhere T; Vera P; Decazes P Ann Nucl Med; 2022 Mar; 36(3):224-234. PubMed ID: 35060071 [TBL] [Abstract][Full Text] [Related]
13. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983 [TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response. Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of the Volumetric Parameters of Dual-Time-Point Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426 [No Abstract] [Full Text] [Related]
17. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567 [TBL] [Abstract][Full Text] [Related]
18. Comparison of prognostic values of primary tumor and nodal Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978 [TBL] [Abstract][Full Text] [Related]
19. The correlation of Qu YH; Long N; Ran C; Sun J Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [TBL] [Abstract][Full Text] [Related]
20. New insight on the correlation of metabolic status on Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]